Video Experimental Relacionado
Updated: Jan 8, 2026

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Un punto de control de toxicidad de citoquinas TAK1 controla la inmunidad anticancerígena
Tirta M Djajawi1, Anne Huber1, Sarahi Mendoza Rivera2
1Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086, Australia.
La quinasa 1 activada por el factor de crecimiento transformante beta (TAK1) protege a las células cancerosas del ataque inmunitario. La inhibición de TAK1 mejora la inmunoterapia contra el cáncer al hacer que los tumores sean más susceptibles a la eliminación mediada por células T.
Videos de Conceptos Relacionados
Tumor Immunotherapy
The JAK-STAT Signaling Pathway
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

